Abstract Rationale: Prostate cancer (PCa) recurrences after surgery frequently occur. To improve the outcome after surgical resection of the tumor, the theranostic multimodal anti-PSMA targeting agent In-111-DTPA-D2B-IRDye700DX was developed and characterized for both pre- and intra-operative tumor localization and eradication of (residual) tumor tissue by PSMA-targeted photodynamic therapy (tPDT), which is a highly selective cancer treatment based on targeting molecules conjugated to photosensitizers that can induce cell destruction upon exposure to near-infrared (NIR) light. Methods: The anti-PSMA monoclonal antibody D2B was conjugated with IRDye700DX and DTPA and subsequently radiolabeled with In-111. To determine the optimal dose and time point for tPDT, BALB/c nude mice with PSMA-expressing (PSMA(+)) s.c. LS174T-PSMA xenografts received the conjugate (24-240 mu g/mouse) intravenously (8 MBq/mouse) followed by mu SPECT/CT, near-infrared fluorescence imaging, and ex vivo biodistribution at 24, 48, 72 and 168 h p.i. Tumor growth of LS174T-PSMA xenografts and overall survival of mice treated with 1-3 times of NIR light irradiation (50, 100, 150 J/cm(2)) 24 h after injection of 80 mu g of DTPA-D2B-IRDye700DX was compared to control conditions. Results: Highest specific tumor uptake was observed at conjugate doses of 80 mu g/mouse. Biodistribution revealed no significant difference in tumor uptake in mice at 24, 48, 72 and 168 h p.i. PSMA(+) tumors were clearly visualized with both mu SPECT/CT and NIR fluorescence imaging. Overall survival in mice treated with 80 mu g of DTPA-D2B-IRDye700DX and 1x 150 J/cm(2) of NIR light at 24 h p.i. was significantly improved compared to the control group receiving neither conjugate nor NIR light (73 days vs. 16 days, respectively, p=0.0453). Treatment with 3x 150 J/cm(2) resulted in significantly prolonged survival compared to treatment with 3x 100 J/cm(2) (p = 0.0067) and 3x 50 J/cm(2) (p = 0.0338). Principal conclusions: In-111-DTPA-D2B-IRDye700DX can be used for pre- and intra-operative detection of PSMA(+) tumors with radionuclide and NIR fluorescence imaging and PSMA-targeted PDT. PSMA-tPDT using this multimodal agent resulted in significant prolongation of survival and shows great potential for treatment of (metastasized) prostate cancer.

Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors

Giulio Fracasso
Investigation
;
Marco Colombatti
Membro del Collaboration Group
;
2019-01-01

Abstract

Abstract Rationale: Prostate cancer (PCa) recurrences after surgery frequently occur. To improve the outcome after surgical resection of the tumor, the theranostic multimodal anti-PSMA targeting agent In-111-DTPA-D2B-IRDye700DX was developed and characterized for both pre- and intra-operative tumor localization and eradication of (residual) tumor tissue by PSMA-targeted photodynamic therapy (tPDT), which is a highly selective cancer treatment based on targeting molecules conjugated to photosensitizers that can induce cell destruction upon exposure to near-infrared (NIR) light. Methods: The anti-PSMA monoclonal antibody D2B was conjugated with IRDye700DX and DTPA and subsequently radiolabeled with In-111. To determine the optimal dose and time point for tPDT, BALB/c nude mice with PSMA-expressing (PSMA(+)) s.c. LS174T-PSMA xenografts received the conjugate (24-240 mu g/mouse) intravenously (8 MBq/mouse) followed by mu SPECT/CT, near-infrared fluorescence imaging, and ex vivo biodistribution at 24, 48, 72 and 168 h p.i. Tumor growth of LS174T-PSMA xenografts and overall survival of mice treated with 1-3 times of NIR light irradiation (50, 100, 150 J/cm(2)) 24 h after injection of 80 mu g of DTPA-D2B-IRDye700DX was compared to control conditions. Results: Highest specific tumor uptake was observed at conjugate doses of 80 mu g/mouse. Biodistribution revealed no significant difference in tumor uptake in mice at 24, 48, 72 and 168 h p.i. PSMA(+) tumors were clearly visualized with both mu SPECT/CT and NIR fluorescence imaging. Overall survival in mice treated with 80 mu g of DTPA-D2B-IRDye700DX and 1x 150 J/cm(2) of NIR light at 24 h p.i. was significantly improved compared to the control group receiving neither conjugate nor NIR light (73 days vs. 16 days, respectively, p=0.0453). Treatment with 3x 150 J/cm(2) resulted in significantly prolonged survival compared to treatment with 3x 100 J/cm(2) (p = 0.0067) and 3x 50 J/cm(2) (p = 0.0338). Principal conclusions: In-111-DTPA-D2B-IRDye700DX can be used for pre- and intra-operative detection of PSMA(+) tumors with radionuclide and NIR fluorescence imaging and PSMA-targeted PDT. PSMA-tPDT using this multimodal agent resulted in significant prolongation of survival and shows great potential for treatment of (metastasized) prostate cancer.
2019
Prostate Specific Membrane Antigen, PSMA
Prostate Cancer
Targeted Photodynamic Therapy
intra-operative
near-infrared fluorescence
File in questo prodotto:
File Dimensione Formato  
2019-Theranostics.pdf

solo utenti autorizzati

Descrizione: Articolo principale
Tipologia: Versione dell'editore
Licenza: Accesso ristretto
Dimensione 1.72 MB
Formato Adobe PDF
1.72 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/997103
Citazioni
  • ???jsp.display-item.citation.pmc??? 28
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 40
social impact